Precision Oncology

Telix Opens Licensing, Co-Development and M&A Talks in Five Areas

Global – October 21, 2026 -- Telix is soliciting partners across five areas of radiopharmaceutical development, with deal structures ranging from licensing and co-development to strategic M&A.

Telix targets therapeutic assets with established proof of concept

In therapeutics, Telix is looking for theranostic oncology programs in urologic and neurologic cancers, other solid tumors and hematologic malignancies. Candidates must have established proof of concept. Telix says they should benefit from its fully integrated radiopharmaceutical platform and strengthen its pipeline, platform and long-term growth.

Likang Takes AI Neoantigen Cancer Vaccine LK101 to Abu Dhabi Summit

Beijing – October 13, 2026 -- Likang Life Sciences, whose lead cancer vaccine candidate LK101 holds clinical trial authorization from China's NMPA (2023) and U.S. FDA IND clearance (2025), will sponsor and exhibit at the Abu Dhabi Future Health Summit 2026 on October 20–22 at the ADNEC Centre.

Likang co-founder joins October 21 oncology panel

Shannon Cheung, Co-Founder and Vice Chairman of Likang, will speak on the panel "The Future of Cancer" on October 21. The session will cover precision oncology and the translation of innovative cancer treatments into clinical practice. It forms part of the summit's Abu Dhabi Blueprints series and will examine the roles of research, investment, policy, and international collaboration in getting new therapies to patients.